A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - A report of the Polish Adult Leukemia Group (PALG)

European Journal of Haematology

Volumn 71, Issue 3, 2003, Pages 155-162

  Wrzesien Kus A ^a   Robak, Tadeusz ^a   Lech Maranda E ^a   Wierzbowska, A ^a   Dmoszynska A ^b   Kowal, M ^b   Holowiecki J ^c   Kyrcz Krzemien S ^c   Grosicki, S ^c   Maj, S ^d   Hellmann, A ^e   Skotnicki, A ^f   Jedrzejczak W ^g   Kuliczkowski, K ^h  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

2 chlorodeoxyadenosine; Acute myeloid leukemia; Arabinoside cytosine; Cladribine; Induction treatment; Purine nucleoside analogs; Refractory

Indexed keywords

CLADRIBINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLERGY; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; PYREXIA IDIOPATHICA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; CYTARABINE; DISEASE-FREE SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; LEUKEMIA, MYELOCYTIC, ACUTE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0042333501     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00122.x     Document Type: Article

References (36)

1. EDENFIELD WJ, GORE SD. Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia. Semin Oncol 1999;26:21-34.
2. ROBAK T, WRZESIEŃ-KUŚ A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymph 2002;43:281-291.
3. KERN W, SCHOCH C, HAFERLACH T, BRAESS J, UNTERHALT M, WORMANN B, BUCHNER T, HIDDEMANN W, for the German AML Cooperative Group. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000;14:226-231.
4. TALLMAN MS, LEE S, SIKIC BI, PAIETTA E, WIERNIK PH, BENNETT JM, ROWE JM. Mitoxantrone, etoposide and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia. Cancer 1999;85:358-367.
5. FERRA C, BERLANGA J, GALLARDO D, ANCIN I, MARIN D, GONZALES JR, PERIS J, MUNOZ J, SARRA J, GRANENA A. Mitoxantrone, etoposide, carboplatinum and Ara-C combination therapy (Meca) in refractory and relapsed acute leukemia. Leuk Lymph 2000;39:583-590.
6. CORTES J, ESTEY E, BERAN M, O'BRIEN S, GILES F, KOLLER C, KEATING M, KANTARJIAN H. Cyclophosphamide, Ara-C, topotecan for patients with refractory or relapsed acute leukemia. Leuk Lymph 2000;36:479-484.
7. LIU YIN JA, WHEATLEY K, REES JK, BURNETT AKon behalf of the UK MRC Adult Leukemia Working Party. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001;113:713-726.
8. ARCHIMBAUD E, THOMAS X, LEBLOND V, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995;13:11-18.
9. HIDDEMANN W, MARTIN WR, SAUERLAND CM, HEINECKE A, BUCHNER T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia; a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990;4:184-188.
10. ROBAK T, WRZESIEŃ-KUŚ A, LECH-MARAŃDA E, KOWAL M, DMOSZYŃSKA A. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymph 2000;39:121-129.
11. JACKSON G, TAYLOR P, SMITH GM, et al. A multicenter, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 2001;112:127-137.
12. CARELLA MA, CASCAVILLA M, GRECO MM, LELILLO M, SAJEVA MR, LADOGANA S, D'ARENA G, PERLA G, CAROTENUTO M. Treatment of poor risk acute myeloid leukemia with fludarabine, cytarabine and G-CSF (Flag regimen): a single centre study. Leuk Lymph 2001;40:295-303.
13. ESTEY E, PLUNKETT W, GANDHI V, RIOS MB, KANTARJIAN H, KEATING M. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymph 1993;9:343-350.
14. KORNBLAU SM, GANDHI V, ANDREEFF HM, BERAN M, KANTARJIAN HM, KOLLER CA, O'BRIEN S, PLUNKETT W, ESTEY E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 1996;10:1563-1569.
15. ROBAK T. Purine nucleoside analogues in the treatment of myeloid leukemia. Leuk Lymph 2003;44:391-409.
16. SEYMOUR JF, HUANG P, PLUNKETT W, GANDHI V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res 1996;2:653-658.
17. ESTEY E, THALL P, ANDREEFF M. Use of G-CSF before, during and after fludarabine plus Ara-C induction therapy of newly diagnosed AML or MDS: comparison with fludarabine + Ara-C without G-CSF. J Clin Oncol 1994;4:671-678.
18. VISANI G, TOSI P, ZINZANI PL, et al. FLAG (fludarabine + high dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemia. Leukemia 1994;8:1842-1846.
19. MONTILLO M, MIRTO S, PETTI MC, LATAGLIATA R, MAGRIN S, PINTO A, ZAGONEL V, MELE G, TEDESCHI A, FERRARA F. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998;58:105-109.
20. NOKES TJC, JOHNSON S, HARVEY D and GOLDSTONE AH. FLAG is a useful regimen for poor prognosis adult myeloid leukemia and myelodysplastic syndromes. Leuk Lymph 1997;27:93-101.
21. HUHMANN IM, WATZKE HH, GEISSLER K, et al. FLAG (fluadarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 1996;73:265-271.
22. FERRARA F, MELILLO L, MONTILLO M, LEONI F, PINTO A, MELE G, MITRO S. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 1999;78:380-384.
23. GORDON MS, YOUNG ML, TALLMAN MS, DRIPE LD, BENNETT JM, PAIETTA E, LONGO W, GERAD H, MAZZA J, ROWE JM. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia. A study of the Eastern Cooperative Oncology Group (ECOG), E5995. Leuk Res 2000;24:871-875.
24. GANDHI V, ESTEY E, KEATING MJ, CHUCRALLAH A, PLUNKETT W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic and molecular interactions. Blood 1996;87:256-264.
25. Hołowiecki J, ROBAK T, KYRCZ-KRZEMIEŃ S, GROSICKI S, WRZESIEŃ-KUŚ A, HELLMANN A, SKOTNICKI A, JEDRZEJCZAK W, KONOPKA L, ZDZIARSKA B. Daunorubicin, cytarabine and 2-CdA(DAC-7) for remission induction in de novo adult acute myeloid leukemia patients. Acta Haematol Pol 2002;33:839-847.
26. CHESON BD, CASSILETH PA, HEAD DR, SCHIFFER CA, BENNETT JM, BLOOMFIELD CD, BRUNNING R, GALE RP, GREVER MR, KEATING MJ. Report of the National Cancer Institute sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-819.
27. SLOVAK ML, KOPECKY KJ, CASSILETH PA, et al. Karyo-typic analysis predicts outcome of pre-remission and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075-4083.
28. ESTEY EH. Treatment of relapsed and refractory acute myeloid leukemia. Leukemia 2000;14:476-479.
29. GORDON MS, YOUNG ML, TALLMAN MD, CRIPE LD, BENNETT JM, PAIETTA E, LONGO W, GERAD H, MAZZA J, ROWE JM. Phase II trial of 2-chlorodeoxyadnosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative oncology Group (ECOG), E5995. Leuk Res 2000;24:871-875.
30. JULIUSSON G, LILIEMARK J. 2-chlorodeoxyadenosine (CDA) with and without cytosine arabinoside (Ara-C) and idarubicin for acute myeloid and lymphoid leukemia-clinical and pharmacokinetic studies. Br J Haematol 1994;87:48a
31. GANDHI V, ESTEY E, KEATING MJ, PLUNKETT W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;11:116-124.
32. KUFE D, SPRIGGS D, EGAN EM, MUNROE D. Relationships among Ara-CTP pools, formation of (Ara-C) DNA and cytotoxicity of human leukemia cells. Blood 1984;64:54-58.
33. KRISTENSEN J, NYGREN P, LILIEMARK J, FRIDBORG H, KILLANDER A, SIMONSSON B, OBERG G, LARSSON R. Interactions between cladribine (2-chlorodeoxyadenosine) and standard anti-leukemia drugs in primary cultures of human tumour cells from patients with acute myelocytic leukemia. Leukemia 1992;8:1712-1717.
34. JULIUSSON G, LOFGREN C, MOLLGARD L, PAUL C, HOGLUND M, TIDEFELT U, BJORKHOLM M. No additional toxicity from cladribine (CdA) when given with cytosine arabinoside and idarubicin (CCI) as primary treatment of acute myeloid leukemia in elderly patients: results from a randomized phase II study from the Leukemia Group of Middle Sweden (LGMS). Blood 2001;98:123a (abstr. 518).
35. FERRARA F, PALMYRA S, POCOLA B, et al. De novo acute myeloid leukemia with multi-lineage dysplasia (MD-AML): treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol 2002;68:203-209.
36. Hołwiecki J, GROSICKI S, ROBAK T, et al. Addition of 2-CdA to daunorubicin and cytarabine results in higher CR rate after a single course of induction treatment in AML and improves outcome in patients with adverse prognostic factors. A randomized, multi-centre phase III study. Blood 2002;100:155a (abstr. 580).